tbuckley/cabot-search huggingface dataset:
Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
Authors: Alba Escalera, Ana S. Gonzalez-Reiche, Sadaf Aslam, Ignacio Mena, Manon Laporte, Rebecca L. Pearl, Andrea Fossati, Raveen Rathnasinghe, Hala Alshammary, Adriana van de Guchte, Keith Farrugia, Yiren Qin, Mehdi Bouhaddou, Thomas Kehrer, Lorena Zuliani-Alvarez, David A. Meekins, Velmurugan Balaraman, Chester McDowell, Jürgen A. Richt, Goran Bajic, Emilia Mia Sordillo, Marion Dejosez, Thomas P. Zwaka, Nevan J. Krogan, Viviana Simon, Randy A. Albrecht, Harm van Bakel, Adolfo García-Sastre, Teresa Aydillo
Journal: Cell Host & Microbe (2022)
Substitution permissible
Authors: W. W. Young
Journal: JAMA (1986)

The authors of "Clinical Overlap Among Medical Diagnosis-Related Groups"1 have described, in my opinion, several serious limitations of the diagnosis-related group (DRG) patient classification. First, understanding the clinical interrelatedness of<i>International Classification of Diseases</i>—Ninth Revision— Clinical Modification (ICD-9-CM) diagnosis codes is critical to the design of a valid patient classification from both a clinical and payment perspective. Second, and equally important, is the way those codes are used to assign patients to categories. The DRG patient classification does not address either of these issues adequately. In fact, as Drs Iezzoni and Moskowitz point out, the problem of clinical overlap is intrinsic to the DRG methodology. Although DRGs may predict hospital resources used on average (eg, average length of stay and average charges or costs of services), they do not define patient types that are clinically specific. Drs Iezzoni and Moskowitz indicate why this is true conceptually and provide examples
Selective induction of apoptosis in the atherosclerotic aortas of apolipoprotein-E deficient mice by short-term thermal therapy Tarun Tewatia, Conjun Wu, XuegingXu, Ki-soo Kil, James T. Willerson, S. Ward Casscells, Yong-Jian Geng. The University of Texas Health Sciences Center at Houston, Houston, TX, The Texas Heart Institute, Houston, TX
Journal: Journal of the American College of Cardiology (2001)
Massachusetts Medical Society
Authors: Earle M. Chapman
Journal: New England Journal of Medicine (1953)

REPORT OF MASSACHUSETTS DELEGATES TO AMERICAN MEDICAL ASSOCIATIONThe following is the report of the Massachusetts delegates to the American Medical Association:The House of Delegates of the American Medical Association, in session June 1 through 5 during the 102nd Annual Meeting of the A.M.A. in New York City, took important policy actions on veterans' medical care, medical ethics, osteopathy, intern training and a wide variety of subjects ranging from medical education to public relations. Highlights of the opening day session of the House were addresses by Dr. Louis H. Bauer, who delivered his term-end report as retiring president; and . . .
Pondering past, future of implantable heart
Authors: Charles Marwick
Journal: JAMA (1985)

What is the immediate future of the implantable "artificial" heart? No clear answer appears to have emerged so far, but an important related question is: Should implantation of the artificial heart at present be restricted to temporary replacement while patients are awaiting a suitable donor heart? Several of the surgeons who have implanted a total cardiac replacement device of one sort or another seem to agree that, pending further improvements in the devices, this is the most practical clinical approach. The surgeons spoke out during a day-long discussion about the use of the artificial device. The discussion was between heart surgeons and journalists—most of whom had reported on the artificial heart developments as they unfolded. The meeting was arranged by the Foundation for American Communications and held in Washington, DC. It was billed as a sort of postmortem examination of how the recent press coverage of the artificial heart affected
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Authors: Farzin Khosrow-Khavar, Seoyoung C Kim, Hemin Lee, Su Been Lee, Rishi J Desai
Journal: Annals of the Rheumatic Diseases (2022)

Recent results from 'ORAL Surveillance' trial have raised concerns regarding the cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA). We further examined this safety concern in the real-world setting.
TCT-537 Stenting of Coronary Bifurcation Lesions with Bioresorbable Everolimus-Eluting Scaffolds. Poznan Bifurcation-Absorb Registry
Authors: Maciej Lesiak, Magdalena Lanocha, Aleksander Araszkiewicz, Andrzej Siniawski, Przemyslaw Mitkowski, Marek Grygier, Wlodzimierz Skorupski, Malgorzata Pyda, Marta Kaluzna-Oleksy, Stanislaw Jankiewicz, Michal Lesiak, Sylwia Iwanczyk, Magdalena Dudek, Stefan Grajek
Journal: Journal of the American College of Cardiology (2017)
Interpreting blood eosinophil counts in health and obstructive lung disease
Authors: Yunus Çolak, Peter Lange
Journal: European Respiratory Journal (2022)

<b>Blood eosinophil count is a well-known measurement that is easy to implement both in hospital and GP settings as a useful biomarker for treatment response in certain types of COPD and asthma</b>https://bit.ly/3sDzCPz
The role of self-peptides in direct T cell allorecognition
Authors: Hossam A. Abdelsamed, Fadi G. Lakkis
Journal: Journal of Clinical Investigation (2021)

Direct allorecognition, the ability of host T cells to recognize intact allogeneic MHC molecules on transplanted tissues, is often assumed to be less dependent on the peptide bound to the MHC molecule than are other antigen recognition pathways. In this issue of the JCI, Son et al. provide unequivocal, in vivo evidence that direct allorecognition depends on the self-peptides bound to the non-self MHC molecule. The authors demonstrate that the induction of allospecific tolerance required the presentation of self-peptides by the non-self MHC molecule, and that only a handful of these peptides accounted for a sizeable proportion of the immunogenicity of the MHC antigen. These are important findings for transplant immunologists because they provide molecular insights into the biology of direct allorecognition, the prime driver of the alloimmune response to MHC-mismatched grafts, and much-needed tools, peptide–MHC multimers, to track and study polyclonal alloreactive T cells.
Isoproterenol-induced sudden deaths in transgenic mice expressing a troponin T mutant linked to familial hypertrophic cardiomyopathy Bjoern C. Knollmann, Neil J. Weissman, Stephen A. Blatt, Kenneth Horton, Fatima de Freitas, James D. Potter. Georgetown University Medical Center, Washington, DC, Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Pharmacologic and ablative hybrid-therapy in atrial fibrillation: Relevance of intravenous propafenone testing Thorsten Lewalter, Lars Lickfett, Christian Wolpert, Alexander Yang, Rainer Schimpf, Berndt Luederitz. Dept. of Cardiology, University of Bonn, Bonn, Germany
Journal: Journal of the American College of Cardiology (2001)
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal
Authors: Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, Ryan D. Nipp
Journal: Journal of the National Comprehensive Cancer Network (2022)

Older adults account for 70% of cancer-related deaths, but previous studies have shown that they are underrepresented in cancer clinical trials. We sought to analyze the representation and outcomes of older adults in trials conducted in the era of novel targeted therapy and immunotherapy.
Association of Policy Interventions With Tobacco Use Behaviors
Authors: Eliseo J. Pérez-Stable, Erik J. Rodriquez
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Atrial fibrillatory frequency predicts atrial defibrillation threshold and early arrhythmia recurrence in patients undergoing internal cardioversion of persistent AF Andreas Bollmann, Maika Mende, Annerose Neugebauer, Dietrich Pfeiffer. University Hospital, Department of Cardiology, Leipzig, Germany, University Hospital, Department of Cardiology, Magdeburg, Germany
Journal: Journal of the American College of Cardiology (2001)
Reply to Francesco Montorsi, Giorgio Gandaglia, Christoph Würnschimmel, Markus Graefen, Alberto Briganti, and Hartwig Huland’s Letter to the Editor re: Paolo Afonso de Carvalho, João A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. Eur Urol 2020;77:628–35. Incredible Results for Robot-assisted Nerve-sparing Radical Prostatectomy …
Authors: Rafael Ferreira Coelho, Paulo Afonso de Carvalho, Giuliano Betoni Guglielmetti, Maurício Dener Cordeiro, William Carlos Nahas
Journal: European Urology (2020)
Small coronary vessel stenting: Primary results and long-term follow-up Petr Kala, Jirina Kosova, Petr Jerabek, Otakar Bocek, Petr Neugebauer, Martin Poloczek, Borivoj Semrad. International and Cardiological Dpt, University Hospital Brno - Bohunice, Brno, Czech Republic
Journal: Journal of the American College of Cardiology (2001)
Error in Affiliations
Journal: JAMA Network Open (2021)

Franziska Maier, PhD; Annika Spottke, MD; Jan-Philipp Bach, MD; Claudia Bartels, PhD; Katharina Buerger, MD; Richard Dodel, MD; Andreas Fellgiebel, MD; Klaus Fliessbach, MD; Lutz Frölich, MD; Lucrezia Hausner, MD; Martin Hellmich, PhD; Stefan Klöppel, MD; Arne Klostermann, MSc; Johannes Kornhuber, MD; Christoph Laske, MD; Oliver Peters, MD; Josef Priller, MD; Tanja Richter-Schmidinger, PhD; Anja Schneider, MD; Kija Shah-Hosseini, PhD; Stefan Teipel, MD; Christine A. F. von Arnim, MD; Jens Wiltfang, MD; Frank Jessen, MD
Correction
Journal: BMJ (1953)

SIR,-I observe in the Supplement of November 28 (p.210) that Lord florder, during an address to the Fellowship for Freedom in Medicine, is reported as saying, " Those who spoke for the whole profession had always declared themselves against a whole-time service, but we were now told that it would not be long before a whole-time service was a fait accompli."In view of the declared policy of the B.M.A., I feel that the identity of Lord Horder's informants should be re- vealed to the profession, and have been surprised to find
Thermal vasodilation therapy improves vascular endothelial function impaired by coronary risk factors Masakazu Imamura, Sadatoshi Biro, Takashi Kihara, Kunitsugu Takasaki, Shinichi Minagoe, Yoshifumi Toyama, Chuwa Tei. First Department of Internal Medicine, Kagoshima University, Kagoshima, Japan, Nanpuh Hospital, Kagoshima, Japan
Journal: Journal of the American College of Cardiology (2001)
Medicolegal
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 259: Controlled Sequential Elevation of the Head and Thorax Combined With Active Compression Decompression Cardiopulmonary Resuscitation and an Impedance Threshold Device Improves Neurological Survival in a Swine Model of Cardiac Arrest
Authors: Johanna C Moore, Bayert Salverda, Michael Lick, Carolina Rojas-Salvador, Guillaume Debaty, Keith Lurie
Journal: Circulation (2019)

Introduction: Survival rates after cardiac arrest with intact brain function remain poor and are not uniformly improved with a single intervention. A bundle of care approach to CPR that enhances cerebral and coronary circulation while simultaneously lowering intracranial pressure (ICP) provides new opportunity to improve neurological survival. Hypothesis: Active compression decompression (ACD) CPR and an impedance threshold device (ITD) to regulate intrathoracic pressure with controlled sequential elevation of the head and thorax (CSE) to lower ICP and increase cerebral and coronary (CoPP) perfusion pressures, will increase neurologically intact survival when compared to a conventional (C) CPR in the flat position in pigs. Methods: Female farm pigs were sedated, intubated, and anesthetized. Central arterial and venous access were continuously monitored. Regional brain tissue perfusion (CerO2) was also measured transcutaneously. Ventricular fibrillation was induced and untreated for 10 minutes. Pigs were randomized to 1) C-CPR flat or 2) CSE ACD+ITD CPR that included 2 min of ACD+ITD with the head and heart first elevated 10 and 8 cm, respectively, and then further elevation over 2 min to 22 and 9 cm, respectively. After 19 min of CPR, pigs were defibrillated and recovered. A veterinarian blinded to the intervention assessed cerebral performance category (CPC) at 24 hours. A neurologically intact outcome was defined as a CPC score of 1 or 2. Categorical outcomes were analyzed by Chi-Square and continuous outcomes with an unpaired student’s t-test. All p-values are unadjusted. Results: Return of spontaneous circulation rate was 8/8 (100%) with CSE and 2/8 (25%) for C-CPR (p = 0.002). For the primary outcome of neurologically intact survival, 6/8 (75%) pigs survived with CPC 1 or 2 with CSE versus 1/8 (12.5%) with C-CPR (p = 0.012). CoPP (mmHg, mean ± SD) was higher with CSE at 18 minutes (41 ± 24 vs 10 ± 5, p = 0.004). CerO2 (%, mean ± SD) and ETCO 2 (mmHg, mean ± SD) values were higher at 18 minutes with CSE (32.2 ± 8.5 vs 16.5 ± 2.1, p = 0.003, and 54.9 ± 8.6 vs 19.1 ± 7.0, p &lt; 0.001), respectively. Conclusions: The novel bundled resuscitation approach of CSE with ACD+ITD CPR increased neurologically intact survival 6-fold versus C-CPR in a swine model of cardiac arrest.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1962)

COMMITTEE ON MATERNAL WELFARE*Eclampsia Followed by Fatal Cerebral HemorrhageA forty-one-year-old gravida 7, para 5, was admitted to the medical service at thirty-six weeks with the diagnosis of acute cholecystitis. She died eighteen hours later.The past history included mild pyelitis, multiple hospital admissions for asthma (none during pregnancy) and thrombophlebitis treated with bishydroxycoumarin (Dicumarol), but 5 previous term pregnancies were said to have been normal. At fourteen weeks the blood pressure was 120 systolic, 80 diastolic, and the weight 70.2 kg. (154 3/4 pounds), but she gained 15.4 kg. (34 pounds) during the next five months without following . . .
Effect of Respiratory Muscle Dysfunction on Pulmonary Function. Studies in Patients with Spinal Cord Injuries
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
Authors: K. H. Begna, J. Kittur, N. Gangat, H. Alkhateeb, M. S. Patnaik, A. Al-Kali, M. A. Elliott, W. J. Hogan, M. R. Litzow, A. Pardanani, C. A. Hanson, R. P. Ketterling, A. Tefferi
Journal: Blood Cancer Journal (2022)

We sought to appraise the value of overall response and salvage chemotherapy, inclusive of allogeneic hematopoietic stem cell transplant (AHSCT), in primary refractory acute myeloid leukemia (prAML). For establishing consistency in clinical practice, the 2017 European LeukemiaNet (ELN) defines prAML as failure to attain CR after at least 2 courses of intensive induction chemotherapy. Among 60 consecutive patients (median age 63 years) correspondent with ELN-criteria for prAML, salvage was documented in 48 cases, 30/48 (63%) being administered intensive chemotherapy regimens and 2/48 consolidated with AHSCT as first line salvage. 13/48 (27%) attained response: CR, 7/13 (54%), CRi, 2/13 (15%), MLFS, 4/13 (31%). The CR/CRi rate was 9/48 (19%), with CR rate of 7/48 (15%). On univariate analysis, intermediate-risk karyotype was the only predictor of response (44% vs 17% in unfavorable karyotype; P = 0.04). Administration of any higher-dose (>1 g/m2) cytarabine intensive induction (P = 0.50), intensive salvage chemotherapy (P = 0.72), targeted salvage (FLT3 or IDH inhibitors) (P = 0.42), greater than 1 salvage regimen (P = 0.89), age < 60 years (P = 0.30), and de novo AML (P = 0.10) did not enhance response achievement, nor a survival advantage. AHSCT was performed in 12 patients with (n = 8) or without (n = 4) CR/CRi/MLFS. 1/2/5-year overall survival (OS) rates were 63%/38%/33% in patients who received AHSCT (n = 12) vs 27%/0%/0% in those who achieved CR/CRi/MLFS but were not transplanted (n = 5), vs 14%/0%/0% who were neither transplanted nor achieved CR/CRi/MLFS (n = 43; P < 0.001); the median OS was 18.6, 12.6 and 5.6 months, respectively. Although CR/CRi/MLFS bridged to AHSCT (n = 8), appeared to manifest a longer median OS (20 months), vs (13.4 months) for those with no response consolidated with AHSCT (n = 4), the difference was not significant P = 0.47. We conclude AHSCT as indispensable for securing long-term survival in prAML (p = 0.03 on multivariate analysis), irrespective of response achievement.
Adjuvant therapy in patients with resected pancreatic adenocarcinoma: Analysis of treatment patterns in a Canadian provincial institution.
Authors: Manik Chahal, Howard John Lim, Janine Marie Davies, Jonathan M. Loree, Daniel John Renouf, Sharlene Gill
Journal: Journal of Clinical Oncology (2021)

e16236 Background: In recent years adjuvant therapy (AT) options for pancreatic cancer have evolved. Compared to gemcitabine (Gem) alone, improved overall survival (OS) was demonstrated first in 2017 with gemcitabine and capecitabine (GemCap), and then further improved in 2018 with FOLFIRINOX. Given these options, we retrospectively reviewed the patterns of AT use in British Columbia (BC), Canada during these periods of availability of newer AT regimens. Methods: Patients (pts) treated at BC cancer centers between January 2017 to June 2018 (“GemCap era”), and July 2018 to December 2019 (“FOLFIRINOX era”), who had undergone curative intent resection and received at least one cycle of AT were included for chart review. Patient and disease characteristics, treatment details, and stated rationale for choice of AT regimen were collected. Analyses were performed with one-way ANOVA for comparison of means between regimens, and Chi-squared or Fisher Exact tests to determine correlation between clinicopathologic factors and likelihood of undergoing a given AT regimen. Results: 148 pts were identified: 67 treated in the GemCap era (Gem: 25, 37%, and GemCap: 42, 63%) and 81 treated in the FOLFIRINOX era (Gem: 26, 32%, GemCap: 20, 25%, FOLFIRINOX: 35, 43%). Examined variables included age, gender, ECOG, T and N stage, margins, lymphovascular invasion and post-operative CA19-9. In the GemCap era, use of GemCap vs. Gem was associated with younger average age (p = 0.001) and positive lymph node status (91% vs. 60%, p = 0.003). In the FOLFIRINOX era, use of Gem AT was associated with a delayed time from surgery to treatment (p = 0.045). AT assignment was not influenced by high volume vs low volume centre in the GemCap era. However, when not assigned treatment with FOLFIRINOX in the FOLFIRINOX era, pts were more likely to receive GemCap in low-volume centers, and more likely to recieve Gem in high-volume centers (p = 0.026). The most common stated reasons for choice of an inferior AT regimen were pt comorbidities or functional status (GemCap era: 24% and FOLFIRINOX era: 35%). In total, 40% of patients treated with GemCap and 49% of patients treated with FOLFIRINOX did not complete the intended treatment, with regimen-specific toxicity accounting for 32% (GemCap) and 29% (FOLFIRINOX) of incomplete treatment. Conclusions: With improvements in survival with newer AT regimens, the majority of pts in our real-world setting were assigned the more efficacious AT regimen. Within the limits of a small sample size, significant pt or disease factors predictive of AT assignment were not identified aside from age and lymph node positivity in the GemCap era, and time from surgery to treatment in the FOLFIRINOX era. However, many pts were not able to complete planned AT due to toxicity. Efforts to optimize pt eligibility to improve FOLFIRINOX tolerability are warranted.